Seeking Alpha

jjjorgen

jjjorgen
Send Message
View jjjorgen's Comments BY TICKER:
  • AEterna May Shoot Over $3/Share In The Near-Term [View article]
    Hey, we're over $3/share!!! He was right!!
    Woops, guess that 6 for 1 reverse split did that.......
    Oct 8, 2012. 06:52 PM | Likes Like |Link to Comment
  • Focus On Perifosine May Shift For AEterna Zentaris Investors [View article]
    One final point for the night- Current Market cap ~ $47.85 million, Cash on hand $45 million. No debt. So, for virtually free, we have Cetrotide earnings of $8 to $9 million/qtr, a great pipeline, partnerships, and future interest in pipeline from larger companies.
    May 30, 2012. 09:33 PM | Likes Like |Link to Comment
  • Focus On Perifosine May Shift For AEterna Zentaris Investors [View article]
    They have 6 months to get their share price above $1/shr. If showing efforts to increase pps, they can request 6 months of extension. What else would you like to know, Happy? Are you familiar Nasdaq De-listing rules?
    May 30, 2012. 06:24 PM | 1 Like Like |Link to Comment
  • Focus On Perifosine May Shift For AEterna Zentaris Investors [View article]
    Findings for Perifosine will be discussed at ASCO, will be nice to hear about trial results finally. Also, a number of things are active with AEterna Zentaris currently, as of May 15th:
    Perifosine: decision to pursue Phase 3 trial in multiple myeloma is based on the following factors:

    o Existing preclinical and clinical data

    o Support among key opinion leaders in this field

    o Market opportunity

    o Examples of other drugs (Avastin, Iressa, Sutent) enjoying success after facing setbacks

    o Reasonable investment (about $2.5M) up to interim analysis in Q1 2013

    Perifosine: Yakult trial in colorectal cancer

    o Meeting planned in third week of May to discuss development plans in this indication in Japan

    o Results from the Phase 3 trial in CRC presented by investigator at ASCO in early June will yield valuable information on perifosine .

    AEZS-108 : why Phase 3 trial in endometrial cancer has not yet been initiated:

    o Doxil which was supposed to be used in this trial is no longer available following FDA decision

    o FDA recommended waiting for Ventana companion diagnostic before starting the trial in order to better screen LHRH positive patients

    o Meeting with Ventana this week to get update on diagnostic test

    AEZS-130: why NDA as diagnostic test for AGHD not yet filed

    o FDA has been coming up with many questions on our document / we have decided to answer all FDA questions before submitting our NDA, thus increasing our chances of presenting a document suited to FDA’s requests

    o Meeting planned with the FDA at end of May to discuss this topic
    May 30, 2012. 05:32 PM | Likes Like |Link to Comment
  • AEterna May Shoot Over $3/Share In The Near-Term [View article]
    I'm in now at $.69/shr. Worth $1/shr with their pipeline. And who knows, perifosine might show validity with other forms of cancer. Also liking AEZS-108
    Apr 4, 2012. 06:15 PM | Likes Like |Link to Comment
  • AEterna Zentaris Looks Ready to Make New Highs [View article]
    Why oh Why another ATM for AEterna??? They said there was plenty of cash. Would be nice not to be so "In the Dark" with this company!
    Jun 29, 2011. 04:57 PM | Likes Like |Link to Comment
  • AEterna Zentaris Looks Ready to Make New Highs [View article]
    Great week for Aeterna. Next week, I'd love to see some type of News Release. Kicking off Phase III of AEZS 108 would hit the spot! Thanks Jeremy for your updates!
    Apr 21, 2011. 08:39 PM | Likes Like |Link to Comment
  • Why AEterna Zentaris Still Retains 200% to 300% Upside Potential [View article]
    Jeremy, where is the update you were promising us? TIA
    Mar 30, 2011. 02:06 PM | Likes Like |Link to Comment
  • Why AEterna Zentaris Still Retains 200% to 300% Upside Potential [View article]
    Nothing really new for progress. They are opening up more clinics worldwide for myeloma, as there is competition for patients with this affliction. Jeremy, your take on this conference call?
    Mar 22, 2011. 07:20 PM | Likes Like |Link to Comment
  • Why AEterna Zentaris Still Retains 200% to 300% Upside Potential [View article]
    Perifosine Phase III results for colorectal cancer will be in 4Q of 2011.
    Good luck to us longs. Listen to the conference call on March 22nd, hopefully it'll be interesting.
    Mar 19, 2011. 10:56 AM | Likes Like |Link to Comment
  • Why AEterna Zentaris Still Retains 200% to 300% Upside Potential [View article]
    We made $11 million last week, yet the PPS did nothing. Simply amazing. Here we are down already this week. I've put every spare penny into this stock currently. Absolutely unbelievable we are still below $2 share. This is one time I'll say, and do, back up the truck, and load up!!
    Mar 15, 2011. 08:18 AM | Likes Like |Link to Comment
  • AEterna Zentaris: Three Near-Term Catalysts Will Continue to Boost Shares [View article]
    Any thoughts on a possible European partner, as you mentioned in December?
    Jan 22, 2011. 01:16 PM | Likes Like |Link to Comment
  • Analysts Say AEterna Zentaris Should Be Valued 200% to 300% Higher [View article]
    I have followed, and am extremely invested in AEZS, and a lesser degree, KERX. I feel strongly positive on both companies. These two biotechs will be shining by end of 2011. I've done a great amount of research, and recommend for all of you to do so also. I'll be happy to see a double on these this year. Good Luck longs!
    Jan 9, 2011. 07:56 PM | Likes Like |Link to Comment
More on AEZS by jjjorgen
COMMENTS STATS
325 Comments
242 Likes